Intestinal strongyloidiasis: recognition, management, and determinants of outcome.
Concha R, Harrington W Jr, Rogers AI.
J Clin Gastroenterol. 2005 Mar;39(3):203-11. doi: 10.1097/01.mcg.0000152779.68900.33.
Intestinal permeability in strongyloidiasis.
Werneck-Silva AL, Sipahi AM, Damião AO, Buchpigue CA, Iriya K, Laudanna AA.
Braz J Med Biol Res. 2001 Mar;34(3):353-7. doi: 10.1590/s0100-879x2001000300009.
[Strongyloidiasis and intestinal malabsorption].
Sipahi A, Laudanna A, Bettarello A.
Rev Hosp Clin Fac Med Sao Paulo. 1979 Jun;34(3):95-7.
Strongyloidiasis-Related IRIS.
Bar-Yoseph H, Zohar Y, Lorber M.
J Int Assoc Provid AIDS Care. 2017 Jan/Feb;16(1):8-10. doi: 10.1177/2325957416673149. Epub 2016 Oct 12.
Intestinal damage in strongyloidiasis: the imbalance between cell death and proliferation.
Werneck-Silva AL, Alvares EP, Gama P, Damião AO, Osaki LH, Ogias D, Sipahi AM.
Dig Dis Sci. 2006 Jun;51(6):1063-9. doi: 10.1007/s10620-006-8010-2.
Strongyloidiasis.
Asano K, Tada S, Kamio T, Matsumoto T, Suko H, Iida M.
Gastrointest Endosc. 2004 Oct;60(4):606-7. doi: 10.1016/s0016-5107(04)01861-9.
Enteric pathogens induce tissue tolerance and prevent neuronal loss from subsequent infections.
Ahrends T, Aydin B, Matheis F, Classon CH, Marchildon F, Furtado GC, Lira SA, Mucida D.
Cell. 2021 Nov 11;184(23):5715-5727.e12. doi: 10.1016/j.cell.2021.10.004. Epub 2021 Oct 29.
Intestinal strongyloidiasis mimicking a tumour.
Schanaider A, Madi K.
Eur J Surg. 1996 May;162(5):429-30.
Clinical conditions associated with intestinal strongyloidiasis in Rio de Janeiro, Brazil.
Cabral AC, Iñiguez AM, Moreno T, Bóia MN, Carvalho-Costa FA.
Rev Soc Bras Med Trop. 2015 May-Jun;48(3):321-5. doi: 10.1590/0037-8682-0019-2015.
Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection.
Terashima A, Alvarez H, Tello R, Infante R, Freedman DO, Gotuzzo E.
Int J Infect Dis. 2002 Mar;6(1):28-30. doi: 10.1016/s1201-9712(02)90132-3.
